返回 Agenda
Session 5: Biosimilars in Practice – Critical Market Opportunities Awaiting to be Seized
Session Chair(s)
Erika Satterwhite
Head of Global Biosimilars Policy
Mylan, United States
The US biologic payer and reimbursement framework has presented challenges for a biologic multi-source market, with a number of barriers blocking meaningful utilization and update. This session focuses on identifying mechanisms to overcome market access barriers in the US and build a suitable environment to release the untapped potential of biosimilar medicines competition.
Learning Objective : At the conclusion of this session, participants should be able to:- Appraise the impact of market barriers on biosimilar use in the US in 2019
- Illustrate, by case studies, the impact on clinical use of biosimilars of common contracting features
- Identify concrete policy solutions which, when implemented, can deliver the most significant improvement in creating a functioning US biosimilars market
Speaker(s)
US Biosimilar Industry Perspective
Juliana Marguerite Reed, MS
The Biosimilars Forum, United States
Executive Director
Global Perspective 2030 on Biosimilars
Murray Aitken, MBA
IQVIA Institute for Human Data Science, United States
Executive Director
Speaker
Elizabeth Jex, JD
Federal Trade Commission, United States
Attorney Advisor, Office of Policy Planning